NeOnc Technologies Holdings Soars 8% on Nasdaq Listing

On March 27, 2025, Neonc's pre-market price was 11.4in.

NeOnc Technologies Holdings, a biotech company developing intranasal and oral therapies for brain cancer, has announced the effectiveness of its registration statement for a direct listing on the Nasdaq. The company registered 2.1 million shares for sale by existing stockholders, with no new capital being raised. The listing is expected to commence on March 26, 2025, under the ticker symbol NTHI.

NeOnc Technologies has been actively expanding its clinical trial network, recently establishing 30 new FDA-compliant research sites to accelerate patient enrollment for brain cancer treatments. This expansion is part of the company's ongoing efforts to advance its Phase 2a trial for NEO100, a purified form of perillyl acid administered intranasally, and its Phase 1/2 trial for NEO212, an oral therapy for primary and secondary brain tumors.

In addition to its clinical advancements, NeOnc Technologies has also secured significant funding. The company successfully completed an $18.5 million financing round in June 2024, providing a substantial capital infusion to support its growth and development. This financial backing, combined with the company's strategic expansions and clinical progress, positions NeOnc Technologies for continued growth and innovation in the biotech sector.